中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 9
Sep.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(9): 1785-1789

Diagnostic value of serum extra-spindle pole-like protein 1 in the progression of hepatitis B virus-related liver fibrosis

DOI: 10.12449/JCH240911

  • Department of Infectious Diseases，The First Affiliated Hospital of Guangxi Medical University，Key Laboratory of High-Incidence-Tumor Prevention and Treatment，Ministry of Education，Nanning 530021，China

Research funding:

National Natural Science Foundation of China (81960115);

National Natural Science Foundation of China (82260124);

National Natural Science Foundation of China (82160123);

Key Laboratory of High-Incidence-Tumor Prevention and Treatment （Guangxi Medical University）, Ministry of Education (GKE-ZZ202107);

Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (GKE-ZZ202218)

More Information
  • Corresponding author: JIANG Jianning， jjianning@163.com （ORCID： 0000-0001-8961-417X）
  • Received Date: 2023-11-26
  • Accepted Date: 2024-02-06
  • Published Date: 2024-09-25
    Abstract
  •   Objective  To investigate the clinical diagnostic value of extra-spindle pole-like protein 1 （ESPL1） in the progression of hepatitis B virus （HBV）-related liver fibrosis.  Methods  A total of 228 patients with HBV infection who were admitted to The First Affiliated Hospital of Guangxi Medical University from June 2017 to August 2023 were enrolled. The transient elastography system FibroScan was used to determine liver stiffness measurement （LSM） for all patients， and according to the LSM value， they were divided into non-liver fibrosis group with 80 patients， mild liver fibrosis group with 83 patients， advanced liver fibrosis group with 30 patients， and liver cirrhosis group with 35 patients. ELISA was used to measure the serum level of ESPL1. The Kruskal-Wallis H test was used for comparison of the serum level of ESPL1 between the four groups； the Spearman correlation analysis was used to investigate the correlation between ESPL1 and LSM； the receiver operating characteristic （ROC） curve was used to analyze the value of serum ESPL1 in predicting the progression of liver fibrosis.  Results  The liver cirrhosis group had a significantly higher serum level of ESPL1 than the non-liver fibrosis group and the mild liver fibrosis group （both P<0.05）， and the advanced liver fibrosis group and the mild liver fibrosis group had a significantly higher serum level of ESPL1 than the non-liver fibrosis group （both P<0.05）. The correlation analysis showed that there was a positive correlation between serum ESPL1 and LSM in the patients with HBV infection and varying degrees of liver fibrosis （r=0.515， P<0.001）. Serum ESPL1 had an area under the ROC curve （AUC） of 0.809 in predicting liver cirrhosis and an AUC of 0.638 in predicting advanced liver fibrosis， with a sensitivity of 87.5% and 100%， respectively， and a specificity of 59.7% and 31.3%， respectively.  Conclusion  There is a certain correlation between serum ESPL1 and HBV-related liver fibrosis， and higher serum ESPL1 may indicate a higher degree of liver fibrosis. Serum ESPL1 is expected to become one of the serum markers for assisting in the diagnosis of liver cirrhosis and an important clinical method for dynamically monitoring the progression of liver fibrosis in patients with HBV infection.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    FATTOVICH G, BORTOLOTTI F, DONATO F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48( 2): 335- 352. DOI: 10.1016/j.jhep.2007.11.011.
    [2]
    CHEN YC, CHU CM, LIAW YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J]. Hepatology, 2010, 51( 2): 435- 444. DOI: 10.1002/hep.23348.
    [3]
    DUBERG AS, LYBECK C, FÄLT A, et al. Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study[J]. Hepatol Commun, 2022, 6( 9): 2418- 2430. DOI: 10.1002/hep4.1974.
    [4]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35( 10): 2163- 2172. DOI: 10.3969/j. issn.1001-5256.2019.10.007.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35( 10): 2163- 2172. DOI: 10.3969/j. issn.1001-5256.2019.10.007.
    [5]
    Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Consensus on clinical application of transient elastography detecting liver fibrosis: A 2018 update[J]. Chin J Hepatol, 2019, 27( 3): 182- 191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会, 等. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27( 3): 182- 191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
    [6]
    AGBIM U, ASRANI SK. Non-invasive assessment of liver fibrosis and prognosis: An update on serum and elastography markers[J]. Expert Rev Gastroenterol Hepatol, 2019, 13( 4): 361- 374. DOI: 10.1080/17474124.2019.1579641.
    [7]
    NEWSOME PN, SASSO M, DEEKS JJ, et al. FibroScan-AST(FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5( 4): 362- 373. DOI: 10.1016/S2468-1253(19)30383-8.
    [8]
    ZHANG X, ZHU GJ, YE XH, et al. Clinical value of GPR parameter model combined with Fibroscan for evaluating the stage of liver fibrosis in patientes with chronic hepatitis B[J]. Chin Hepatol, 2022, 27( 8): 877- 880. DOI: 10.14000/j.cnki.issn.1008-1704.2022.08.010.

    张鑫, 朱桂娟, 叶晓航, 等. GPR参数模型联合Fibroscan对慢性乙型肝炎肝纤维化的诊断效能[J]. 肝脏, 2022, 27( 8): 877- 880. DOI: 10.14000/j.cnki.issn.1008-1704.2022.08.010.
    [9]
    BACAC M, FUSCO C, PLANCHE A, et al. Securin and separase modulate membrane traffic by affecting endosomal acidification[J]. Traffic, 2011, 12( 5): 615- 626. DOI: 10.1111/j.1600-0854.2011.01169.x.
    [10]
    WANG RM, ZANG WW, HU BB, et al. Serum ESPL1 can be used as a biomarker for patients with hepatitis B virus-related liver cancer: A Chinese case-control study[J]. Technol Cancer Res Treat, 2020, 19: 1533033820980785. DOI: 10.1177/1533033820980785.
    [11]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(2022 version)[J]. Chin J Infect Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
    [12]
    KANDA T, GOTO T, HIROTSU Y, et al. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: A review[J]. Int J Mol Sci, 2019, 20( 6): 1358. DOI: 10.3390/ijms20061358.
    [13]
    LAMPROYE A, BELAICHE J, DELWAIDE J. Le FibroScan: une nouvelle méthode d’évaluation non invasive de la fibrose hépatique[The FibroScan: a new non invasive method of liver fibrosis evaluation][J]. Rev Med Liege, 2007, 62 Spec No: 68- 72.
    [14]
    AKIMA T, TAMANO M, HIRAISHI H. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis[J]. Hepatol Res, 2011, 41( 10): 965- 970. DOI: 10.1111/j.1872-034X.2011.00846.x.
    [15]
    JEONG PY, KUMAR A, JOSHI PM, et al. Intertwined functions of separase and caspase in cell division and programmed cell death[J]. Sci Rep, 2020, 10( 1): 6159. DOI: 10.1038/s41598-020-63081-w.
    [16]
    SINGLETON MR, UHLMANN F. Separase-securin complex: A cunning way to control chromosome segregation[J]. Nat Struct Mol Biol, 2017, 24( 4): 337- 339. DOI: 10.1038/nsmb.3393.
    [17]
    WIRTH KG, WUTZ G, KUDO NR, et al. Separase: A universal trigger for sister chromatid disjunction but not chromosome cycle progression[J]. J Cell Biol, 2006, 172( 6): 847- 860. DOI: 10.1083/jcb.200506119.
    [18]
    RUPPENTHAL S, KLEINER H, NOLTE F, et al. Increased separase activity and occurrence of centrosome aberrations concur with transformation of MDS[J]. PLoS One, 2018, 13( 1): e0191734. DOI: 10.1371/journal.pone.0191734.
    [19]
    MUKHERJEE M, GE GQ, ZHANG NG, et al. Separase loss of function cooperates with the loss of p53 in the initiation and progression of T- and B-cell lymphoma, leukemia and aneuploidy in mice[J]. PLoS One, 2011, 6( 7): e22167. DOI: 10.1371/journal.pone.0022167.
    [20]
    JUNG KS, KIM SU, AHN SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement(FibroScan)[J]. Hepatology, 2011, 53( 3): 885- 894. DOI: 10.1002/hep.24121.
    [21]
    HU BB, WANG RM, LIANG HK, et al. Expression of ESPL1 gene in hepatocellular carcinoma tissue and its role in the prognosis assessment[J]. Chin Hepatol, 2023, 28( 3): 285- 289. DOI: 10.14000/j.cnki.issn.1008-1704.2023.03.008.

    胡伯斌, 王荣明, 梁蘅恺, 等. ESPL1基因在肝细胞癌组织中的表达及其在预后评估中的作用[J]. 肝脏, 2023, 28( 3): 285- 289. DOI: 10.14000/j.cnki.issn.1008-1704.2023.03.008.
    [22]
    DENG DL. Objective to evaluate the value of peripheral blood in the diagnosis of hepatocellular carcinoma and prediction of recurrence[D]. Nanning: Guangxi Medical University, 2021.

    邓德丽. 评估血清ESPL1对HBV相关肝细胞癌的诊断及预测复发的价值[D]. 南宁: 广西医科大学, 2021.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (142) PDF downloads(22) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return